Abstract:Fenofibrate, as a lipid-lowering drug, has been reported to have a protective effect on the retina independent with plasma lipid levels. This study aimed to investigate that the ameliorative effects of fenofibrate on systemic and retinal inflammation, as well as gut microbiota dysbiosis in high-fat diet (HFD)-induced mice. C57BL/6J mice were randomly allocated into four groups: standard diet (SD) group; HFD group; SD plus fenofibrate (SD_ Fe) group; HFD plus fenofibrate (HFD_ Fe) group. After successfully establishing models (5 months), indicators associated with lipid, gut barrier, inflammation and gut microbiota were investigated. Our results showed that supplementing the HFD with fenofibrate decreased body weight gain, alleviated dyslipidemia and reversed the downregulation of short-chain fatty acid (SCFAs) in serum, retina and feces. Fenofibrate ameliorated intestinal barrier function damage in HFD-induced mice. Fenofibrate coadministration inhibited the levels of inflammatory factor and lipopolysaccharide (LPS) in the serum and attenuated inflammatory response in the retina of HFD-induced mice. Systemic LPS was positively correlated with a series of inflammatory factors in serum and retina, respectively. Fenofibrate supplementation down-regulated the abundances of LPS-associated bacteria in HFD mice, including Firmicutes and Proteobacteria at the phylum level, Desulfovibrionaceae at the family level, as well as unclassified_ Desulfovibrionaceae , Acetatifactor , Flavonifractor , Oscillibacter and Anaerotruncus at the genus level. However, fenofibrate treatment up-regulated the abundances of SCFA-associated bacteria in HFD mice, including Bacteroidetes at the phylum level, Porphyromonadaceae at the family level, as well as unclassified_Porphyromonadaceae , Barnesiella , Alloprevotella and Bifidobacterium at the genus level. In conclusion, our results confirmed fenofibrate could attenuate HFD-induced systemic and retinal inflammation, accompanying with restoration of intestinal barrier damage and modulation of gut microbiota/metabolites. This work provided an explanation for the ameliorative effects of fenofibrate on HFD-induced systemic and retinal inflammation might be partially related with the modulation of gut microbiota and its metabolites.

Fenofibrate enhances lipid deposition via modulating PPAR, SREBP-1c, and gut microbiota in <i>ob/ob</i> mice fed a high-fat diet

PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]

Fenofibrate Improves Vascular Endothelial Function and Contractility in Diabetic Mice

Fenofibrate Ameliorated Systemic and Retinal Inflammation and Modulated Gut Microbiota in High-Fat Diet-Induced Mice

Efficacy And Safety Of Fenofibrate As An Add-On In Patients With Elevated Triglyceride Despite Receiving Statin Treatment

Fenofibrate attenuates renal lipotoxicity in uninephrectomized mice with high-fat diet-induced obesity

Fenofibrate Reduces Serum Retinol-Binding Protein-4 by Suppressing Its Expression in Adipose Tissue

Fenofibrate Alleviates Insulin Resistance and Hepatic Steatosis Via Modulation of Let-7/ SERCA2b Axis

Fenofibrate improves hepatic steatosis, insulin resistance, and shapes the gut microbiome via TFEB-autophagy in NAFLD mice

Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice

Fenofibrate Ameliorates Insulin Resistance in Lipoprotein Lipase Heterozygous Knockout Mice and Its Possible Mechanisms

Fenofibrate Increases Serum Vaspin by Upregulating Its Expression in Adipose Tissue.

Upregulation of Hepatic VLDLR Via PPARα is Required for the Triglyceride-Lowering Effect of Fenofibrate.

Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function

[The effect of fenofibrate on expression of genes involved in fatty acids beta-oxidation and associated free-radical processes]

Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice

Fenofibrate Enhances Cd36 Mediated Endocytic Uptake and Degradation of Oxidized Low Density Lipoprotein in Adipocytes from Hypercholesterolemia Rabbit

Fenofibrate alleviates the composition and metabolic pathways of gut microbiota in high-fat diet treated hamsters

Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver

Induction of the Phospholipid Transfer Protein Gene Accounts for the High Density Lipoprotein Enlargement in Mice Treated with Fenofibrate*

Fenofibrate induces liver enlargement in aging mice via activating the PPARα-YAP signaling pathway